Center for Children and Families, Florida International University, Department of Psychology, 11200 SW 8th Street, AHC1 Rm. 140, Miami, FL 33199, USA.
Center for Children and Families, Florida International University, Department of Psychology, 11200 SW 8th Street, AHC1 Rm. 140, Miami, FL 33199, USA.
Addict Behav. 2018 Oct;85:43-50. doi: 10.1016/j.addbeh.2018.05.010. Epub 2018 May 15.
Co-use of cannabis and drugs other than cannabis (DOTC) influences the risk of experiencing cannabis disorders. Accordingly, we explored whether speed of transition to drug co-use, the number of DOTC used, and/or being an experimental cannabis-only user, a regular cannabis-only user, or a regular cannabis user who co-uses DOTC (i.e., cannabis-plus user) were associated with decision-making (DM), mental health disorder symptoms, or cannabis use-related characteristics.
We analyzed baseline data from a sub-sample of 266 adolescent (ages 14 to 16) cannabis users (CU) participating in an ongoing longitudinal study. Assessments included semi-structured interviews, self-report questionnaires, and measures of drug use, DM (measured via the Iowa Gambling Task), mental health disorders, and cannabis use-related problems.
Endorsing a larger number of mood disorders symptoms was associated with being a regular cannabis-plus user rather than a regular cannabis-only user (AOR = 1.08, C.I.95% 1.01, 1.15). Poorer DM was associated with a faster transition to co-use, such that for each one unit increase in DM performance, the years to onset of drug co-use increased by 1% (p = 0.032). Endorsing a larger number of cannabis use-related problems was positively associated with endorsing a larger number of DOTC used (p = 0.001).
This study provides new evidence on the process of drug co-use among CU. Specifically, mood disorder symptoms were associated with use of DOTC among regular CU. Furthermore, poorer DM was associated with a faster transition to drug co-use. Poorer DM and mood disorder symptoms may aggravate or accelerate the onset of adverse consequences among adolescent CU.
大麻与大麻以外的药物（DOTC）共同使用会影响大麻障碍的风险。因此，我们探讨了向药物共同使用转变的速度、使用的 DOTC 数量以及是否为仅吸食大麻的实验性使用者、仅吸食大麻的常规使用者或同时使用大麻和 DOTC 的常规使用者（即大麻加用者）与决策制定（DM）、心理健康障碍症状或与大麻使用相关的特征有关。
我们分析了一项正在进行的纵向研究中 266 名青少年（14 至 16 岁）大麻使用者（CU）亚样本的基线数据。评估包括半结构化访谈、自我报告问卷以及药物使用、DM（通过爱荷华赌博任务测量）、心理健康障碍和与大麻使用相关的问题的测量。
更多的心境障碍症状与作为常规大麻加用者而不是常规大麻使用者相关（AOR=1.08，95%CI 1.01，1.15）。DM 较差与更快地过渡到共同使用相关，即 DM 表现每增加一个单位，药物共同使用的发病年龄增加 1%（p=0.032）。与更多的大麻使用相关问题相关联与使用更多的 DOTC 呈正相关（p=0.001）。
本研究为 CU 中药物共同使用的过程提供了新的证据。具体而言，心境障碍症状与常规 CU 中 DOTC 的使用有关。此外，DM 较差与更快地过渡到药物共同使用有关。较差的 DM 和心境障碍症状可能会加重或加速青少年 CU 不良后果的发生。
